NCT04145622
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 dose escalation phase
Exclusions: Patients with prior treatment of B7-H3 targeted agent or a topoisomerase I inhibitor (e.g. trastuzumab deruxtecan (DS-8201)
https://ClinicalTrials.gov/show/NCT04145622